Basic Research in Cardiology

, Volume 99, Issue 2, pp 94–100 | Cite as

The natriuretic peptides in heart failure

FOCUSSED ISSUE: Natriuretic peptides

Abstract.

Synthesis and release of the natriuretic peptides rises incrementally with increasing degrees of cardiac dysfunction. The prime stimulus is intracardiac distending pressures with modulating influences including age, gender, renal function and other aspects of neurohormonal status. Measurements of plasma natriuretic peptide concentrations and of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide, in particular, show promise in diagnosis of heart failure, risk stratification in those with known heart disease, and in adjustment of therapy. Recombinant B-type natriuretic peptide itself can be administered as a treatment. These diagnostic, prognostic and therapeutic applications of B-type natriuretic peptide require a considerable expansion beyond current evidence, but it appears likely that the true role of plasma peptide measurements and peptide administration will become firmly established within the coming 5 year period.

Key words

Cardiac natriuretic peptides B-type natriuretic peptide amino-terminal pro-B-type natriuretic peptide atrial natriuretic peptide heart failure 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Steinkopff Verlag 2004

Authors and Affiliations

  1. 1.Christchurch Cardioendocrine Research GroupChristchurch School of Medicine and Health SciencesChristchurchNew Zealand

Personalised recommendations